» Articles » PMID: 35394614

HIV-1 Subtype C Tat Exon-1 Amino Acid Residue 24K is a Signature for Neurocognitive Impairment

Overview
Journal J Neurovirol
Publisher Springer
Specialties Microbiology
Neurology
Date 2022 Apr 8
PMID 35394614
Authors
Affiliations
Soon will be listed here.
Abstract

Variation and differential selection pressures on Tat genes have been shown to alter the biological function of the protein, resulting in pathological consequences in a number of organs including the brain. We evaluated the impact of genetic variation and selection pressure on 147 HIV-1 subtype C Tat exon 1 sequences from monocyte-depleted peripheral lymphocytes on clinical diagnosis of neurocognitive impairment. Genetic analyses identified two signature amino acid residues, lysine at codon 24 (24K) with a frequency of 43.4% and arginine at codon 29 (29R) with a frequency of 34.0% in individuals with HIV-associated neurocognitive impairment. The analyses also revealed two signature residues, asparagine, 24 N (31.9%), and histidine, 29H (21.3%), in individuals without neurocognitive impairment. Both codons, 24 and 29, were associated with high entropy but only codon 29 was under positive selection. The presence of signature K24 increased by 2.08 times the risk of neurocognitive impairment, 3.15 times higher proviral load, and 69% lower absolute CD4 T-cell count compared to those without the signature. The results support a linkage between HIV-1 C Tat N24K polymorphism, proviral load, immunosuppression, and neurocognitive impairment. The signature may induce more neurotoxic effects, which contributes to establishment and severity of HIV-associated neurocognitive impairment.

Citing Articles

The association between HIV-1 Tat and Vif amino acid sequence variation, inflammation and Trp-Kyn metabolism: an exploratory investigation.

Williams M, Asia L, Lindeque Z, Jansen Van Vuren E BMC Infect Dis. 2024; 24(1):943.

PMID: 39251983 PMC: 11385500. DOI: 10.1186/s12879-024-09874-0.


Association of combination antiretroviral therapy with risk of neurological diseases in patients with HIV/AIDS in Taiwan: a nested case-control study.

Chou C, Chiou J, Ho M, Tien N, Li T, Chiu M Front Pharmacol. 2023; 14:1110605.

PMID: 37361207 PMC: 10285306. DOI: 10.3389/fphar.2023.1110605.


Effect of Chinese herbal medicine therapy on risks of all-cause mortality, infections, parasites, and circulatory-related mortality in HIV/AIDS patients with neurological diseases.

Chiou J, Chou C, Ho M, Tien N, Liang W, Chiu M Front Pharmacol. 2023; 14:1097862.

PMID: 36937878 PMC: 10020503. DOI: 10.3389/fphar.2023.1097862.

References
1.
Ajasin D, Eugenin E . HIV-1 Tat: Role in Bystander Toxicity. Front Cell Infect Microbiol. 2020; 10:61. PMC: 7052126. DOI: 10.3389/fcimb.2020.00061. View

2.
Albini A, Benelli R, Giunciuglio D, Cai T, Mariani G, Ferrini S . Identification of a novel domain of HIV tat involved in monocyte chemotaxis. J Biol Chem. 1998; 273(26):15895-900. DOI: 10.1074/jbc.273.26.15895. View

3.
Allen T, OConnor D, Jing P, Dzuris J, Mothe B, Vogel T . Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature. 2000; 407(6802):386-90. DOI: 10.1038/35030124. View

4.
Antinori A, Arendt G, Becker J, Brew B, Byrd D, Cherner M . Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007; 69(18):1789-99. PMC: 4472366. DOI: 10.1212/01.WNL.0000287431.88658.8b. View

5.
Bagashev A, Sawaya B . Roles and functions of HIV-1 Tat protein in the CNS: an overview. Virol J. 2013; 10:358. PMC: 3879180. DOI: 10.1186/1743-422X-10-358. View